


Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations

Study population



61.8 - 79.8% of patients met international biologic criteria

EUFOREA 2021	% meets criteria	EPOS/EUFOREA 2023 criteria	% meets criteria
History of ESS and/or at least 1 SCS course last year	91.0%	History of surgery	92.6%
Severe (NPS ≥4)	71.4%	Type-2 (BEC ≥150 cells/ul and/or serum total IgE ≥100 IU/ml)	92.5%
Uncontrolled (SNOT-22 ≥35 or VAS TSS ≥50 or NB ≥50 or LoS ≥52)	90.0%	3 out of 5: Type-2 or ≥2 SCS courses or impaired QoL or impaired smell or asthma	88.0%
Uncontrolled Severe CRSwNP and History and Severe Uncontrolled	61.8%	CRSwNP and prior surgery and meets 3 out of 5 Uncontrolled Severe criteria	79.8%

Study centres



6 centres in 5 EU countries

Dupilumab is effective whether international biologic criteria are met or not

